4Front Ventures (FFNTF) Looking to Have Best Prices in Cannabis Industry

By |

Watch

Midas Letter

The Digital Businesss Channel for Cannabis, Crypto and Technology Stocks.

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.

4Front Ventures Corp (OTCMKTS:FFNTF) (CNSX:FFNT) is a multi-state cannabis operator and retailer who mass-produces low-cost branded cannabis products.

You may remember Midas Letters coverage of Cannex Capital Holdings. (Most recently, Cannex Sets Sights on California Cannabis and Extracts Market) Well, 4Front merged with Cannex to become a publicly-traded entity and utilize Cannex’s assets and skillsets. Cannex was recognized as being one of the best producers of scale in the industry.

Founder & President Kris Krane has over twenty years working in the cannabis industry and has dedicated his career to reforming misguided drug policies. We sat down with Kris to discuss the company’s operations in Illinois, Massachusetts, California, Michigan, and Washington, the opportunities with the new Biden administration, and how the company is competing with the industry’s major players.

Watch this exclusive interview to find out the latest from 4Front Ventures.

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.